Physician profile
Taylor Blanton
NPI 1407642051
$1,198.93
in general payments reported to CMS, 2019-2025
24 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,198.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $185.19 | 2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $103.59 | 2025 | |
| Janssen Biotech, INC. | $96.66 | 2025 | Tecvayli, Rybrevant, Talvey |
| Incyte Corporation | $91.81 | 2025 | Jakafi, Monjuvi |
| Tempus Ai, INC | $84.45 | 2025 | Xt Cdx |
| Celgene Corporation | $63.39 | 2025 | Reblozyl |
| Merck Sharp & Dohme LLC | $60.48 | 2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $58.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.65 | 2025 | Fruzaqla, Iclusig |
| Eisai INC. | $52.86 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $44.83 | 2025 | Lynozyfic |
| Pfizer INC. | $38.41 | 2025 | |
| Glaxosmithkline, LLC. | $33.38 | 2025 | Zejula, Jemperli |
| Alexion Pharmaceuticals, INC. | $27.69 | 2025 | Ultomiris |
| Lilly USA, LLC | $25.56 | 2025 | Verzenio, Jaypirca |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $25.41 | 2025 | |
| Abbvie INC. | $24.65 | 2025 | |
| Gilead Sciences, INC. | $24.08 | 2025 | Trodelvy |
| Geron Corporation | $22.40 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $18.18 | 2025 | |
| Rigel Pharmaceuticals, INC. | $17.65 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Caris Mpi, INC. | $17.07 | 2025 | Mi Cancer Seek |
| Genentech USA, INC. | $16.84 | 2025 | Itovebi |
| Iovance Biotherapeutics, INC. | $10.63 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Blanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.